SCHEMBL3136530

SCHEMBL3136530

CCN1C(=O)S/C(=C/c2ccc(-c3ccccc3N)o2)C1=S

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 4/20 0.53
MAP3K5 Q99683 4/20 0.44
ITGB2 P05107 1/20 0.44
ITGAM P11215 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
INSR P06213 1/20 0.43
IGF1R P08069 1/20 0.43
ENPP2 Q13822 1/20 0.43
STAT3 P40763 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
POLB P06746 4/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
GRK2 P25098 1/20 0.43
DNMT1 P26358 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3136522 1.00 TNFRSF1A (0.53) TNFRSF1AMAP3K5ITGB2ITGAMCASP3
SCHEMBL3136535 1.00 TNFRSF1A (0.53) TNFRSF1AMAP3K5ITGB2ITGAMCASP3
SCHEMBL3135831 0.88 PIK3CA (0.56) TNFRSF1AMAP3K5ITGB2ITGAMCASP3
SCHEMBL3135824 0.88 PIK3CA (0.56) TNFRSF1AMAP3K5ITGB2ITGAMCASP3
SCHEMBL3135820 0.88 PIK3CA (0.56) TNFRSF1AMAP3K5ITGB2ITGAMCASP3
SCHEMBL3136571 0.87 INSR (0.59) TNFRSF1AMAP3K5ITGB2ITGAMINSR
SCHEMBL3136564 0.87 INSR (0.59) TNFRSF1AMAP3K5ITGB2ITGAMINSR
SCHEMBL3136575 0.87 INSR (0.59) TNFRSF1AMAP3K5ITGB2ITGAMINSR
SCHEMBL3129314 0.87 MAP3K5 (0.58) TNFRSF1AMAP3K5ITGB2ITGAMCASP3
SCHEMBL3129316 0.87 MAP3K5 (0.58) TNFRSF1AMAP3K5ITGB2ITGAMCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 US claimed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 WO claimed
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 US disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 TNFRSF1A 2355/4885MAP3K5 3869/4885ITGB2 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.